CNTRL
CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.
Overview
Involved in cell cycle progression and cytokinesis. During the late steps of cytokinesis, anchors exocyst and SNARE complexes at the midbody, thereby allowing secretory vesicle-mediated abscission.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.71, affected pathway 0.94, genetic association 0.00, somatic mutation 0.45). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Thymoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.
- 1 · What it is
CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.
- 2 · What goes wrong in cancer
Involved in cell cycle progression and cytokinesis. During the late steps of cytokinesis, anchors exocyst and SNARE complexes at the midbody, thereby allowing secretory vesicle-mediated abscission.
- 3 · How drugs use it
No product in this corpus aims at CNTRL yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1858 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q7Z7A1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000119397 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: leukaemia 0.57 (GraphQL API, CC0)); IntOGen CNTRL (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Involved in cell cycle progression and cytokinesis. During the late steps of cytokinesis, anchors exocyst and SNARE complexes at the midbody, thereby allowing secretory vesicle-mediated abscission. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Midbody, Midbody ring (UniProt). Locus 9q33.2 (HGNC).
- Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Cutaneous squamous cell carcinoma: IntOGen driver in 1 cohort (CSCC)
- Thymoma: IntOGen driver in 1 cohort (THYM)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CNTRL" OR ABSTRACT:"CNTRL" OR TITLE:"centriolin" OR ABSTRACT:"centriolin" OR TITLE:"Centriolin" OR ABSTRACT:"Centriolin" OR TITLE:"CEP1" OR ABSTRACT:"CEP1" OR TITLE:"CEP110" OR ABSTRACT:"CEP110") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CNTRL, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGTF2I
- TargetHDAC4
Shares Thymoma (WHO types A, AB, B1, B2 and B3), IntOGen, Open Targets Platform.
- TargetZNF331
Shares Nasopharyngeal carcinoma, IntOGen, Open Targets Platform.
- TargetMLLT3
Shares Leukaemia (all types), IntOGen, Open Targets Platform.
- TargetHNRNPA2B1
Shares Leukaemia (all types), IntOGen, Open Targets Platform.
- TargetNUTM2D
Shares Nasopharyngeal carcinoma, IntOGen.
- TargetZNF626
Shares Nasopharyngeal carcinoma, IntOGen.
- TargetZNF680
Shares Nasopharyngeal carcinoma, IntOGen.